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Abstract 
Standard integration-proficient lentiviral vectors (IPLVs) are effective at much lower doses than 
other vector systems and have shown promise for gene therapy of Parkinson’s disease. Their 
main drawback is the risk of insertional mutagenesis. The novel biosafety-enhanced integration-
deficient lentiviral vectors (IDLVs) may offer a significant enhancement in bio-safety, but have 
not been previously tested in a model of a major disease. We have assessed bio-safety and 
transduction efficiency of IDLVs in a rat model of Parkinson’s disease, using IPLVs as a 
reference. Genomic insertion of lentivectors injected into the lesioned striatum was studied by 
linear amplification-mediated PCR, followed by deep sequencing and insertion site analysis, 
demonstrating lack of significant IDLV integration. Reporter gene expression studies showed 
efficient, long-lived and transcriptionally targeted expression from IDLVs injected ahead of 
lesioning in the rat striatum, albeit at somewhat lower expression levels than from IPLVs. 
Transgenic human glial cell line-derived neurotrophic factor (hGDNF) expression from IDLVs 
was used for a long-term investigation of lentivector-mediated, transcriptionally targeted 
neuroprotection in this Parkinson’s disease rat model. Vectors were injected before striatal 
lesioning and the results showed improvements in nigral dopaminergic neuron survival and 
behavioral tests regardless of lentiviral integration proficiency, although they confirmed lower 
expression levels of hGDNF from IDLVs. These data demonstrate the effectiveness of IDLVs in 
a model of a major disease and indicate that these vectors could provide long-term Parkinson’s 
disease treatment at low dose, combining efficacy and bio-safety for targeted central nervous 
system applications. 
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Introduction 
Lentiviral vectors and adeno-associated viral vectors (AAVs) have been widely used for pre-
clinical and some clinical gene therapies in the central nervous system (CNS) (Abordo-Adesida 
and others 2005; Bjorklund and others 2000). Retroviral vector integration has mediated some 
serious adverse events in clinical trials (Hacein-Bey-Abina and others 2003) and although 
lentiviral vectors have a safer profile (Aiuti and others 2013; Biffi and others 2011), some 
examples of feline lentiviral vector-mediated oncogenesis have been reported in foetal models 
(Condiotti and others 2013; Nowrouzi and others 2013; Themis and others 2005). In contrast, 
integration-deficient lentiviral vectors (IDLVs) have provided similar transduction efficiencies 
to classical integration-proficient lentiviral vectors (IPLVs) in a range of cell types, whilst 
having a significantly reduced risk of insertional mutagenesis (Wanisch and Yáñez-Muñoz 
2009; Yáñez-Muñoz and others 2006). IDLVs are commonly produced using class I integrase 
mutations (most frequently encoding a D64V change), whereby viral DNA fails to integrate into 
the host genome and forms episomal DNA circles instead. As these viral episomes lack 
replication signals, they are stable in quiescent cells but progressively diluted in proliferating 
cells. Hence, IDLVs are ideally suited for applications in the post-mitotic CNS environment 
(Peluffo and others 2013), but to our knowledge they have not been previously applied in the 
study of a major disease. Additionally, most experiments using IDLVs have focused on a 
relatively short time scale (weeks), with very few studies so far confirming efficient and long-
lasting CNS gene expression in vivo (Apolonia and others 2007; Hutson and others 2012; 
Philippe and others 2006; Rahim and others 2009; Yáñez-Muñoz and others 2006). 
Parkinson’s disease (PD) affects over 6 million individuals worldwide and is considered the 
second most common neurodegenerative disease, after Alzheimer’s disease (Lyons and Pahwa 
2011). PD is an idiopathic disorder caused by the loss of dopaminergic neurons in the substantia 
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nigra pars compacta (SNpc) and subsequent depletion of dopamine levels in the striatum (Chen 
and others 2005). Protection of the scant remaining dopaminergic neurons has been suggested as 
a therapeutic stratagem since the discovery of neuroprotective effects of glial cell line-derived 
neurotrophic factor (GDNF) on dopaminergic neurons in vitro (Lin and others 1993). GDNF 
exerts its effects by regulating cell survival and cell differentiation through PI3K/Akt and 
Ras/ERK pathways (Toth and others 2002). The potential neuroprotection and neurorestoration 
effects of GDNF have been examined in both rodent and non-human primate models of PD with 
positive effects shown in a variety of them (Eslamboli and others 2003; Kirik and others 2000; 
Pascual and others 2008). These encouraging results then prompted initial open-label clinical 
trials, which suggested continuous delivery of GDNF (or its relative, neurturin) by protein 
infusion or viral vector-mediated delivery was efficacious in advanced PD patients (Gill and 
others 2003; Marks and others 2008). However, such results were not replicated in double-blind, 
phase II clinical trials (Lang and others 2006; Marks and others 2010). At this time, the 
mechanism underlying the uneven success of GDNF in these trials is unclear (Broadstock and 
Yáñez-Muñoz 2012). Viral vector-mediated delivery offers stability of expression but, once 
administered, expression of the neurotrophic factor is often constitutive. Therefore, it is crucial 
that such expression is both safe and well-tolerated. The use of viral vectors allows 
transcriptional targeting, which may also be beneficial (Hioki and others 2007; Jakobsson and 
others 2003; Li and others 2010). Further trials are being considered to search for an effective, 
safe, and stable vector-based system to deliver GDNF (Bartus and others 2011; Richardson and 
others 2011).  
Following on these investigations, we have assessed the efficacy of the novel IDLVs for therapy 
in a PD rodent model. We report that IDLVs can provide efficient, long-lived and 
transcriptionally targeted transduction of brain cells when injected ahead of striatal lesioning. 
While hGDNF gene expression was higher from IPLVs, transduction with IDLVs resulted in 
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equally efficient neuroprotection and long-term improvements of behavioral symptoms in 6-
OHDA-lesioned rats. Lack of significant IDLV integration was confirmed in animals injected 
with vector following striatal lesioning. These results underscore the effectiveness of IDLVs in 
the CNS and the scope for low-dose, low-risk therapies based on these novel vectors. 
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Materials and Methods 
Lentiviral vector production and titration 
Concentrated stocks of the 2
nd
 and 3
rd
 generation lentiviral vectors, both IPLVs and IDLVs, 
were produced by calcium phosphate transfection into HEK-293T cells as previously described 
(Yáñez-Muñoz and others 2006). Lentiviral transfer plasmids used in this study were pRRLsc-
CMVp-eGFP-W, pRRLsc-hGFAPp-eGFP-W, and pHR’-hGFAPp-hGDNF-W. All vectors were 
self-inactivating, contained a central polypurine tract/central termination sequence (cPPT/cTS) 
and Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and were 
pseudotyped with the vesicular stomatitis virus G protein (VSV-G) envelope. Viral titers were 
quantified by either flow cytometry using a FACSCanto II (BD Biosciences, UK) or qPCR using 
a Rotogen Q (QIAgen, UK) as described (Yáñez-Muñoz and others 2006), or by p24 ELISA kit 
(SAIC, Frederick, Maryland, USA) following the manufacturer’s instructions.  
Animals 
All animal experiments were performed in accordance with the UK Animals (Scientific 
Procedures) Act, 1986. Forty-five male Sprague-Dawley rats (Charles River, UK) weighing 
250-300 g at the start of the study were housed 2-3 rats/cage. Animals were maintained in a 
standard 12-hour light/dark cycle with free access to food and water. 
Stereotaxic injection  
Animals were kept under isoflurane anesthesia (5% in 100% O2 for induction and 2.5% in 100% 
O2 for maintenance). The nose bar was set at -3.3 mm. All injections were made using a 20 µl 
Hamilton syringe held within an automated syringe pump (World Precision Instruments), and 
the injection rate was 0.5 µl/min. 
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6-OHDA lesioning and lentiviral vector injections for vector integration analysis 
Thirty minutes prior to surgical procedures, animals were injected with a combined solution of 
pargyline (5 mg/kg, i.p) and desipramine (25 mg/kg, i.p). A single injection of 6-OHDA (12.5 
µg in 2.5 µl of 0.9% saline and 0.02% ascorbic acid) was made into the median forebrain bundle 
(co-ordinates from Bregma: AP -2.8; ML +2.0; DV – 9.0 mm). Animals were then allowed to 
recover for two weeks. To assess the effectiveness of 6-OHDA lesioning, animals were 
habituated in 40 cm flat-bottomed hemispherical bowls for 15 min. Animals were then injected 
with apomorphine hydrochloride (Tocris, UK; 1 mg/kg, i.p, dissolved in sterile water). 
Rotational behavior was scored for 30 min post-injection. Animals displaying at least four net 
contraversive rotations per minute were deemed to have over 90% loss of striatal dopamine 
terminals (Hefti and others 1980).  
Four days following apomorphine injection, under isofluorane-induced anesthesia, animals 
received a single 2.5 µl injection of either IDLV-CMVp-eGFP (2x10
8
 eGFP vector 
particles/ml), IPLV-CMVp-eGFP (2x10
8
 eGFP vector particles/ml) or DMEM (PAA, UK) into 
the left striatum (co-ordinates from Bregma: AP +1.0; DV -5.0; ML +2.8 mm). Groups of 
animals were as follows: 6-OHDA-lesioned IDLV (n = 5), 6-OHDA-lesioned IPLV (n = 4), 
non-lesioned IDLV (n = 3), non-lesioned IPLV (n = 3), and non-lesioned vehicle (n = 2). One 
week post-vector injection, animals were killed by exposure to a rising concentration of CO2 
followed by cervical dislocation. The striata were rapidly dissected into RNAlater for 
subsequent LAM-PCR. 
Integration site analyses by 3’LTR-mediated LAM-PCR 
3’LTR LAM-PCR was performed as previously described to determine the lentiviral vector 
integration sites (Schmidt and others 2007). In brief, 400-1100 ng of DNA per sample was used 
for linear PCR to pre-amplify 3’ vector genome junctions. After double-strand synthesis, 
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restriction digestion (Tsp509I and HpyCH4IV) and adapter ligation, two nested exponential 
PCRs were performed. LAM-PCR amplicons were prepared for sequencing by 454 technology 
(454/Roche system) as previously described (Paruzynski and others 2010). A final PCR step was 
set up to include 454 sequencing adaptors and sample-specific barcodes. After sequencing, the 
obtained sequences were trimmed and aligned to the rat genome (assembly rn4) by a semi-
automated bioinformatical data mining pipeline as previously described (Arens and others 
2012).  
Lentiviral vector injections and 6-OHDA lesioning to test neuroprotective effects 
Animals received a single injection of either IPLV-GFAPp-hGDNF (n = 10), IDLV-GFAPp-
hGDNF (n = 10), IPLV-GFAPp-eGFP (n = 5) or IDLV-GFAPp-eGFP (n = 5) into two sites of 
the right striatum (5 µl/site; 10
9
 viral DNA copies/ml or 2x10
4
 ng p24/ml). Stereotaxic co-
ordinates from Bregma: (1) AP +1.8; ML -2.5; DV -5.0 mm; (2) AP 0.0; ML -3.5; DV -5.0 mm. 
Two weeks post-vector transduction, animals were injected with a combined solution of 
pargyline (5 mg/kg, i.p) and desipramine (25 mg/kg, i.p). Thirty minutes later, 6-OHDA (2.5 
µg/µl in 0.9% sterile saline and 0.02% ascorbic acid) was injected into the same locations as 
vector administration, 2 µl/ site. Reagents were obtained from Sigma Aldrich, UK, unless stated 
otherwise. 
Amphetamine-induced rotational behavior in hGDNF-treated animals 
Rotational tests were performed from three weeks after 6-OHDA lesioning, once per month for a 
period of 4 months. Animals were acclimatized in 40 cm diameter bowls for 30 min prior to 
injection with amphetamine (Sigma, UK, 5 mg/kg, i.p, dissolved in sterile water). The rotations 
were assessed for 90 min post-injection as one whole head to tail revolution, with contralateral 
and ipsilateral rotations counted separately.  
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GDNF detection by ELISA  
Animals were sacrificed by cervical dislocation as described above. The striata were isolated 
and frozen immediately in liquid nitrogen. Tissues were homogenized in complete lysis buffer 
(Roche, UK) followed by a centrifugation at 14000 g, 4
o
C for 15 min. Levels of GDNF were 
determined by hGDNF ELISA kit (Promega, UK) following the manufacturer’s instructions. 
Immunohistochemistry  
Rat brains were collected, fixed in ice-cold 4% PFA and maintained at 4
o
C for 3 days. Coronal 
sections were sliced at 50 µm thickness on a vibratome (Campden Instruments, UK) following 
an incubation in 1% BSA blocking buffer for an hour. Rabbit anti-TH antibody (Cat AB152, 
1:1000, Millipore, UK) was added to sections containing the SN, whilst either mouse anti-NeuN 
(Cat MAB377, 1:500, Millipore, UK), rabbit anti-GFAP (Cat Z0334, 1:500, DAKO, UK) or 
rabbit anti-Iba1 (Cat 019-19741, 1:500, WAKO, UK) antibody was added to striatal sections. 
Sections were maintained at 4
o
C overnight then washed and incubated with either goat anti-
mouse AlexaFluor555 (Cat A21424, 1:500, Invitrogen, UK) or goat anti-rabbit AlexaFluor555 
(Cat A21428, 1:500, Invitrogen, UK) antibody for an hour, in the dark. After another three 
washes in 1X PBS, sections were incubated with 1 µg/ml DAPI for 15 min and subsequently 
washed in 1X PBS before being mounted onto SuperFrost slides.  
Image capture  
Brain sections were visualized under an inverted fluorescence Axio Observer D1 microscope. 
Images were captured with an AxioCam combined with AxioVision software. Equipment and 
software were from Carl Zeiss, UK. 
Cell counts 
Overlapping parts from each section containing the SN were captured and stitched automatically 
by AxioVision software to create a mosaic image of the section. The number of TH+ cells 
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within the SNpc (identified through Paxinos and Watson Rat Brain Map, 6
th
 edition, 2007) on 
each section was counted manually using ImageJ software. Cell counts from approximately 30 
SNpc-containing serial sections were averaged to obtain the total TH+ cell number per section 
of the SNpc in the corresponding brain hemisphere.  
Measurement of eGFP intensity 
After image capture, the area of the striatum on each section was subsequently identified 
according to the Paxinos and Watson Rat Brain Map (6
th
 edition, 2007). The eGFP intensity 
within this area was quantified by AxioVision software and divided by the area to obtain the 
value of eGFP intensity, expressed as arbitrary units per µm
2
. The values for approximately 60 
striatal sections from each brain were averaged to obtain the value for the corresponding brain. 
Statistical analysis 
Using Prism 5 software (GraphPad, San Diego, California, USA), data were analyzed and shown 
as means ± S.E.M, with error bars representing the S.E.M. “n” refers to the number of animals 
per group. Comparisons of statistical significance were assessed by one- or two-way ANOVA 
followed by Bonferroni’s post-hoc test or 2-tailed Student's t-test. Significant levels were set at 
*p < 0.05, **p < 0.01, ***p < 0.001.   
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Results 
Residual integration levels of IDLVs in intact and lesioned rat striata 
We and others have demonstrated that IDLVs only integrate at residual levels in a variety of 
tissues, including the CNS (Chick and others 2012; Mátrai and others 2011; Yáñez-Muñoz and 
others 2006). To confirm that this is also the case in the 6-OHDA-lesioned rat brain we 
performed comparative large-scale lentiviral insertion site analysis by linear amplification-
mediated PCR (LAM-PCR) followed by high-throughput sequencing (pyrosequencing). 
Animals were lesioned with 6-OHDA or mock-treated, and 18 days later injected in the right 
striata with IDLV or IPLV expressing eGFP. One week after vector injection, striata were 
harvested and analyzed for vector integration. As expected, there were considerably fewer 
integration sites for IDLVs than IPLVs (Table 1). Most interestingly, frequencies of integration 
events were broadly similar within vector types when comparing lesioned and non-lesioned 
striata. These data suggest that disease status had no effect on the overall integration frequency 
of lentiviral vectors. Supp Table 1 details the integration sites of IDLVs in the present study. 
 
Lentiviral vector-mediated eGFP expression in the striatum of 6-OHDA-lesioned rats 
Animals were injected with IPLV- and IDLV-GFAPp-eGFP vectors, followed by 6-OHDA 
lesioning two weeks later. Brain tissue was harvested 5 months post vector injection. We firstly 
demonstrated successful transduction with widespread eGFP production within the striatum 
(Figs. 1a,b). Cell identification by morphology and marker expression indicated specific cell 
types were targeted, with mainly astrocytes being transduced; no significant microglia or neuron 
transduction was noticed (Figs. 1c,d). Levels of eGFP in groups treated with IDLVs were about 
2-fold lower than in those receiving IPLVs (Fig. 1e). No eGFP expression in the non-injected 
hemisphere (Fig. 2a) or anterograde expression in the SNpr (Fig. 2b) was detected. Our data 
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suggest a modest, spatially restricted activation of both astrocytes and microglia in the area 
surrounding the injection site (Figs. 2c,d). 
 
hGDNF neuroprotection on dopaminergic neurons in the SNpc of 6-OHDA-lesioned rats  
GDNF is naturally secreted by glial cells (Lin and others 1993), and complications from 
neuronal transgene expression are possible (Jakobsson and Lundberg 2006). Following this 
rationale, we employed an astrocyte-specific promoter, the glial fibrillary acidic protein 
promoter (GFAPp), to drive lentivector-mediated GDNF expression in our neuroprotection 
experiments. Animals were injected with IPLV- or IDLV-GFAPp-hGDNF vectors, using eGFP-
expressing vectors as controls, followed two weeks later by 6-OHDA lesioning. Levels of 
hGDNF (measured by ELISA 5 months post-injection) in ipsilateral striata of rats receiving 
hGDNF vectors were 60 to 250-fold higher than in contralateral striata or in eGFP-treated rats. 
We also observed a five-fold difference in hGDNF levels between IPLV- and IDLV-hGDNF-
treated groups, higher in the former (Fig. 3).  
We investigated the potential neuroprotective effects of hGDNF on dopaminergic neurons by 
estimating the loss of TH+ cells in the SNpc five months post vector injection and lesioning. 
Following a 10 µg striatal injection of 6-OHDA, a 50% reduction from normal levels of 
dopaminergic cell bodies was detected in the ipsilateral hemisphere of control (eGFP-treated) 
groups. The reduction was only 30% in hGDNF-treated animals, with no statistical difference 
between IPLVs and IDLVs despite the 5-fold difference in hGDNF levels (p =0.48, Fig. 4a). 
Figs. 4b-d show representative images of the SN with no damage in the contralateral 
hemisphere, 30% TH+ cell loss in the ipsilateral hemisphere of hGDNF-treated groups and 50% 
TH+ cell loss in the ipsilateral hemisphere of eGFP-treated groups, respectively. These data 
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indicate an effective neuroprotection by hGDNF on dopaminergic neurons regardless of 
lentiviral integration proficiency. 
 
Behavioral recovery of hGDNF-treated rats 
The vector-injected and 6-OHDA-lesioned animals were subjected to amphetamine-induced 
rotational tests performed monthly, starting from 3 weeks post-lesioning. Animals showed a 
normal weight gain with no difference between groups (p = 0.59, Fig. 5a). A time-dependent 
reduction in number of rotations was observed in all groups (Fig. 5b). However, an extensive 
recovery, with 98% reduction in rotational turns by the third test, was only seen in hGDNF-
treated animals, regardless of vector integration-proficiency. In contrast, those injected with 
eGFP vectors presented only 66% reduction. Furthermore, we detected significant differences in 
rotational behavior between eGFP- and hGDNF-treated groups within tests, starting from the 
second test. By quantifying the number of rotations at 10 minute intervals, we noted that these 
differences occurred from minute 50 onwards (Figs. 6a-d). These results demonstrate that 
higher hGDNF expression resulting from IPLV administration (Fig. 3a) does not lead to any 
significant difference in the behavioral recovery compared to IDLVs (p = 0.36).  
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Discussion 
Since we and others first reported safe and efficient in vivo transduction with IDLVs (Philippe 
and others 2006; Yáñez-Muñoz and others 2006), there has been scope for application to gene 
therapy for a major disease. Here we have investigated IDLV transduction for PD gene therapy 
in an animal model, in direct comparison with the commonly used IPLVs. Our data demonstrate 
that IDLVs injected ahead of striatal lesioning support long-lasting transduction of CNS cells for 
at least 5 months post-administration. We report a sustained therapeutic effect in this animal 
model following such IDLV-mediated neuroprotection, which was not significantly different to 
that of their integrating counterparts and persisted for the duration of the experiment.  
Lentiviral vectors are an attractive system for gene therapy, with many positive features derived 
from their biology and extensive vector development, such as large transgene capacity of up to 8 
kb, low immunogenicity (Mátrai and others 2010), enhanced cell-specific targeting through 
pseudotyping (Cannon and others 2011) and relatively simple production (Dull and others 
1998). Moreover, they can transduce many cell types of the CNS (Jakobsson and others 2003), 
including dividing as well as non-dividing cells, with stable long-term expression of transgene(s) 
(Cockrell and Kafri 2007). Effective transgene expression can be obtained at low vector doses, 
3-4 logs lower than AAVs, which have been widely used in gene therapy for PD treatment. 
Using lentiviral vectors, therefore, may be a significant advantage considering the potential of 
side-effects which may be associated with high vector doses (Bartus and others 2011; Drinkut 
and others 2012). However, a significant obstacle in the routine clinical use of current IPLVs is 
the potential for insertional mutagenesis and subsequent oncogenesis caused by integration of 
the viral genome into the host cell genome (Biasco and others 2012). This risk could be 
addressed by using IDLVs if the target cell population does not divide significantly (Banasik 
and McCray 2010; Wanisch and Yáñez-Muñoz 2009).  
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In the current work, we have assessed striatal integration of stereotaxically injected lentiviral 
vectors in normal rats or rats previously lesioned with 6-OHDA. Using LAM-PCR followed by 
pyrosequencing, we have only observed marginal integration levels of IDLVs, in agreement 
with previous analyses of IDLV integration in vivo (Chick and others 2012; Mátrai and others 
2011; Yáñez-Muñoz and others 2006). Extending previous observations, we noticed that such 
residual integration did not change significantly in the presence of the striatal lesion. 
Due to the lack of integration, transgene expression induced following IDLV administration can 
be reduced by cell division, though a similar disadvantage is well-known in the equally 
replication-deficient AAVs. In addition, although transcriptional targeting through the use of 
cell-type specific promoters may be beneficial (Hioki and others 2007; Jakobsson and others 
2003; Li and others 2010), the GFAPp promoter may be less efficient in an episomal 
configuration, as observed with some promoters (Wanisch and Yáñez-Muñoz 2009). Astrocyte 
proliferation stimulated following CNS injury would therefore be predicted to result in less 
effective astrocytic eGFP or hGDNF expression following transduction with IDLV-GFAPp than 
IPLV-GFAPp. However, the stimulation of proliferation is temporary (Drinkut and others 2012) 
and rarely observed in the pathophysiology of PD (Mirza and others 2000). Indeed the results 
from this study indicate that proliferation and episomal expression were no major obstacles, with 
IDLV vectors driven by GFAPp expressing moderately lower levels of eGFP (2-fold) and 
hGDNF (5-fold) than their integrating counterparts. Moreover, high levels of hGDNF expression 
may be disadvantageous (Georgievska and others 2004). Using lentiviral vector-mediated 
intrastriatal delivery, these authors demonstrated that hGDNF levels above 700 pg/mg tissue 
weight caused a down-regulation of striatal TH levels and a significant reduction in mRNA level 
of this enzyme in the SN. Although the reductions might be restored 4-8 weeks later (Cohen and 
others 2011), it is unclear whether these changes may in turn affect striatal dopamine levels. The 
IDLVs here provided safe levels of hGDNF that were about 3-fold less than the reported over-
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expression threshold. Importantly, the beneficial therapeutic effects of IDLV-hGDNF on 
survival of nigral dopaminergic cells were as efficient as those from IPLVs, which surpassed the 
700 pg/mg threshold.  
Numerous studies (Ciesielska and others 2011; Drinkut and others 2012; Jakobsson and others 
2003; Richardson and others 2011) have previously reported that striatal transgene expression 
targeted to neurons resulted in transgene products in the SNpc/pr, the globus pallidus, and the 
subthalamic nucleus, in both lesioned and unlesioned hemispheres. This was possibly due to 
retrograde delivery from striatal dopaminergic nerve terminals to the cell bodies in the SNpc 
(Tomac and others 1995) and anterograde axonal transport from striatal neurons to the afferent 
regions via the indirect pathway, plus axonal sprouting between the two striatal hemispheres 
(Ciesielska and others 2011; Richardson and others 2011). These off-target effects may provide 
some advantages in GDNF application for PD treatment, but levels of GDNF transported 
indirectly to these afferent regions are unpredictable, particularly when higher vector doses or 
longer expression times are required (Bartus and others 2011; Drinkut and others 2012). It also 
remains unclear what the adequate level of GDNF required by these regions is, in order to 
provide therapeutic effects and simultaneously minimize side-effects (Georgievska and others 
2004). In the light of the possible complications from neuronal transgene expression, we chose 
to target expression to astrocytes (Jakobsson and Lundberg 2006). Whilst neuronal axons can be 
several centimetres long, astrocytic protrusions rarely extend more than 20 μm from the cell 
body. Such a natural physical barrier may diminish off-target expression of transgene(s). In fact, 
the present study demonstrated astrocytic-eGFP expression targeted by IPLV- or IDLV-GFAPp 
vectors mainly in the injected striatum; a small proportion of cells in the white matter were 
transduced, presumably as a result of the backflow that occurs following withdrawal of the 
injection needle (Jakobsson and others 2003). Such an approach may therefore lead to maximal 
transgene expression in the required brain region, whilst preventing off-target effects resulting 
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from ectopic expression in afferent regions. Moreover, since astrocytes are the major source of 
GDNF upon brain injury and may be responsible for maintenance of GDNF levels in the SN of 
PD brains (Mogi and others 2001; Saavedra and others 2008), astrocytic-hGDNF expression by 
the lentiviral vector-GFAPp would be beneficial as demonstrated in this study. 
One further advantage of lentiviral vectors is the minimal stimulation of the immune response 
that may occur following transgene delivery (Abordo-Adesida and others 2005; Mátrai and 
others 2010). Indeed, we only detected an elevated density of activated microglia and astrocytes 
surrounding the needle tract, which most likely reflects physical damage following injection of 
vectors and/or 6-OHDA rather than immune system activation following cell transduction 
(Batchelor and others 1999). This finding is consistent with previous studies (Drinkut and others 
2012; Jakobsson and others 2003) regardless of whether lentiviral vectors or AAVs were used. 
In the current study the astrogliosis was prolonged up to 5 months, the end of the experiment, 
whereas Drinkut and colleagues reported that activated cells disappeared 3 months post-injection 
(Drinkut and others 2012). A possible explanation can be that in our study both vectors and 6-
OHDA were administered into the same location, with concomitant doubling of physical trauma 
to the brain regions following repeated injections. As such, our approach may cause more 
physical damage than vector injection into the brain separated from intraperitoneal injection of 
MPTP in the previous study.  
The neuroprotective effects of GDNF were also confirmed here through an improvement in 
amphetamine-induced rotational asymmetry of treated animals. Rats with a partial 6-OHDA 
lesion (less than 70% nigral dopaminergic cell loss) improve their rotational behavior over time, 
returning to nearly normal by about week 16 post-lesioning (Stanic and others 2003). This may 
be a consequence of regeneration of striatal dopaminergic terminals induced by GDNF or BDNF 
secreted from activated microglia in the injured striatum (Batchelor and others 1999). Such 
findings may explain the reduction in the number of rotations in all animal groups observed 
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here. However, only those animals injected with hGDNF-expressing vectors displayed an 
essentially complete recovery of behavior, which started from week 9 following vector injection. 
This recovery occurred regardless of vector integration proficiency. 
In the present study, we chose to test a neuroprotection approach in which hGDNF lentivectors 
were administered prior to 6-OHDA lesioning. This strategy should be optimal for prevention of 
axonal retraction and subsequent neuronal death and indeed rendered a positive outcome. 
However, in PD patients the effects of neurotrophic factor therapy may also include 
neurorestoration of damaged neurons and neuroregeneration with new neurons in the injured 
regions. Therefore, further assessment of the effectiveness of IDLV-hGDNF expression for PD 
should include an experimental strategy in which 6-OHDA lesioning precedes the injection of 
therapeutic vector. 
In summary, our study demonstrates IDLV-mediated neuroprotection in rats when intrastriatal 
hGDNF expression precedes 6-OHDA-lesioning. These data also show promoter-mediated cell-
type specificity from IDLVs, with a focus on effective astrocytic transgene expression. We 
demonstrate both efficient delivery and long-lasting expression of a therapeutically relevant 
transgene by IDLVs at low dose. We also demonstrate lack of significant IDLV integration in 
this PD lesion model, supporting these safer vectors as potential tools in gene therapy for PD 
treatment, and by extension for other major diseases of the CNS. Our data warrant further 
exploration of IDLVs in PD-relevant models, in particular non-human primates, prior to 
considering clinical application. Demonstration of safety and efficacy in such models would 
strongly support the use of IDLVs in first-in-man studies. 
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Figure legends 
Figure 1. eGFP expression in rat striata. The right striata were injected with IPLV- or IDLV-
GFAPp-eGFP two weeks prior to unilateral 6-OHDA lesioning at the same position of vector 
administration. Representative serial striatal sections from (a) IPLV- and (b) IDLV-eGFP 
injected animals show both vector injection site and area of vector spread. Representative high-
magnification images from (c) IPLV- and (d) IDLV-eGFP-injected striata, respectively, are 
shown. Cell-type identification by morphology and marker expression indicated the majority of 
eGFP+ cells were astrocytes (GFAP+); no significant microglia (Iba1+) or neuron (NeuN+) 
transduction was observed. Nuclei were stained blue with DAPI; scale bar: 2000 µm (a,b), 100 
µm (c,d) and 20 µm (insets in c,d). (e) eGFP levels evaluated 5 months post-vector injection 
showed a two-fold difference between IPLVs and IDLVs. Data were analyzed for statistical 
significance by 2-tailed Student t- test; error bars represent the S.E.M; n = 3 per group; **p < 
0.01. 
 
Figure 2. Lack of anterograde eGFP transport and restricted glial activation. Following 
striatal injection of IDLV-GFAPp-eGFP and unilateral 6-OHDA lesioning at the same site, (a) 
no IDLV-eGFP expression in the non-injected left hemisphere or (b) anterograde eGFP 
transport from the striatum to the SNpr (co-stained in red for TH+ cells) was detected. Glial 
activation was analysed by GFAP+ or Iba1+ staining (in red), respectively. Arrows indicate 
activated (c) astrocytes and (d) microglia surrounding the IDLV injection site, with images on 
right side additionally displaying eGFP production pattern. Nuclei were stained blue with DAPI; 
scale bar: 2000 µm (a), 1000 µm (c,d) and 500 µm (b). 
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Figure 3. hGDNF overexpression in injected striata. Five months after vector transduction 
and 6-OHDA lesioning, rat striata were harvested. Levels of hGDNF measured by ELISA 
showed no differences in the contralateral hemispheres between groups. In contrast, the levels of 
hGDNF detected in the ipsilateral hemispheres of hGDNF-treated groups (n = 10) were 
significantly higher than in eGFP-treated groups (n = 4). There was also a significant difference 
between IPLV- and IDLV-GDNF-treated groups. Statistical analysis with one-way ANOVA and 
Bonferroni’s post-hoc test. Error bars represent the S.E.M; **p<0.01, ***p<0.001. 
 
Figure 4. Effect of hGDNF expression on survival of dopaminergic neurons in the SNpc. 
(a) Five months after vector transduction and 6-OHDA lesioning, counts of TH+ cells in the 
SNpc from contralateral and ipsilateral striata demonstrated similar cell survival in the 
contralateral SNpc of all groups and the loss of about 50% TH+ cells in the ipsilateral SNpc of 
eGFP-treated groups (n = 10). Animals receiving hGDNF showed enhanced cell survival, with 
70% TH+ cells remaining in both IPLV- and IDLV-treated groups (n = 10). (b-d) 
Representative images of the SN with (b) no damage in the contralateral hemisphere; (c) 30% 
TH+ cell loss in the ipsilateral hemisphere of hGDNF-treated groups; and (d) 50% TH+ cell loss 
in the ipsilateral hemisphere of eGFP-treated groups. Red cells are TH+; scale bar = 500 µm. 
Statistical analysis with one-way ANOVA and Bonferroni’s post-hoc test. Error bars represent 
the S.E.M; **p<0.01, ***p<0.001. 
 
Figure 5. hGDNF-mediated improvement in amphetamine-induced rotational movement. 
(a) Time-scale of the experiment superimposed on a weight gain chart, with no statistical 
difference in weight between groups at each time point. (b) Following 30 min acclimation, 
animals were injected with amphetamine and net 360
o
 rotations were scored for 90 min. 
hGDNF-treated groups showed a significantly improved recovery of behavior starting from the 
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2
nd
 monthly test, with similar improvements regardless of vector integration proficiency. Data 
were analyzed for statistical significance by two-way ANOVA and Bonferroni’s post-hoc test. 
Error bars represent the S.E.M; n = 10 per group; *p<0.05. 
 
Figure 6. Timing of hGDNF-mediated improvement in rotational behavior in lesioned rats. 
(a-d) Following 30 min acclimation, animals were injected with amphetamine and net 360
o
 
rotations were scored every 10 min for 90 min in monthly rotational tests. The improved 
behavior in hGDNF-treated groups noted from the 2
nd
 test is due to lower rotation numbers from 
min 50. Data were analyzed for statistical significance by two-way ANOVA and Bonferroni’s 
post-hoc test. Error bars represent the S.E.M; n = 10 per group; *p<0.05. 
 
Table 1: Residual integration of IDLVs is not affected by striatal lesion status 
 
 Integration sites 
Lesioned Non-lesioned 
Exactly mappable 
IDLV 9 8 
IPLV 1023 494 
Total 
IDLV 18 8 
IPLV 1142 555 
  
The following groups of animals were analyzed: lesioned IDLV (n = 5), lesioned IPLV (n = 
4), non-lesioned IDLV (n = 3), non-lesioned IPLV (n = 3). LAM-PCR samples were 
subjected to high-throughput pyrosequencing. The raw sequence data were processed to 
determine possible integration sites. These were mapped onto the rat genome, with the 
majority being exactly mappable and few multiple hits. A total of 104601 sequence reads 
were obtained, distributed as follows: lesioned IDLV (38917), lesioned IPLV (38162), non-
lesioned IDLV (15080), non-lesioned IPLV (12442).  
  

   
   
   
   
 
Supplementary Table 1. Integration events of IDLVs in rat striata 
Status Animal Sample DNA  Reads Chr Sequence 
Orientation 
 
IL Identity Genomic 
Length 
 
Upstream 
of TTS [bp] 
 
In Gene 
Distance 
to TSS 
[bp] 
 
Intron 
Exon 
% in 
Gene 
Downstream 
of Gene 
 
RefSeq 
Gene 
Gene 
length 
Gene 
Orientation 
RefSeq ID Missing LTR 
Bases 
Non-lesioned 14 15 877 1 19 + 49172372 99.3 142  665199 In5 62.288  Cdh13 1067948 + NM_138889 10 
Non-lesioned 14 15 877 2 2 + 77471363 100 128  51847 In2 35.366  Fam134b 146602 + NM_001034912 1 
Non-lesioned 14 15 877 1 2 + 77471406 100 85  51890 In2 35.395  Fam134b 146602 + NM_001034912 20 
Non-lesioned 15 21 697 27 10 - 40385868 98.48 66  53815 In25 96.6  Anxa6 55709 - NM_024156 0 
Non-lesioned 15 21 697 1 17 - 51216107 100 4-23(23) 11165     Trim27 12351 - NM_001134974 0 
Non-lesioned 16 27 1000 145 1 - 81102788 100 2-30(31) 79302     Cyp2s1 15023 - NM_001107495 0 
Non-lesioned 16 27 1000 1 16 + 88133136 100 4-23(24) 1806159     Slc10a2 243838 + NM_017222 0 
Non-lesioned 16 27 1000 5 6 - 47958552 100 81  67188 In16 94.775  Tpo 70892 - NM_019353 0 
Lesioned 6 51 397 3 8 - 69935674 100 3-22(24)  673 In1 4.868  Oaz2 13824 + NM_001109899 0 
Lesioned 7 57 535 1 16 + 20336721 96.84 96     71149 MGC72612 13960 + NM_001009538 0 
Lesioned 7 57 535 2 16 - 79570945 95 20  8691 Ex3 87.886  Cln8 9889 - NM_001007686 0 
Lesioned 7 57 535 1 17 + 35793267 99.65 286 275621     Cdyl 227392 - NM_001014145 0 
Lesioned 7 57 535 1 17 + 69041211 100 20  82169 In2 14.027  Ryr2 585775 + NM_032078 0 
Lesioned 7 57 535 1 3 - 56124081 100 20     19972 Chn1 42613 - NM_032083 0 
Lesioned 7 57 535 1 4 + 114228958 100 92  85027 In1 10.668  Lrrtm4 797018 + NM_001134746 0 
Lesioned 7 57 535 1 23 - 79829941 100 3-25(35) 382941     Mageb18 2253 - NM_001044246 0 
Lesioned 8 63 904 2032 2 - 220111914 98.57 2-281(281)  4653 In4 29.554  Mettl14 15744 - NM_001106470 0 
 
Chr, Chromosome; IL, Integration Locus; TSS Transcription start site 
